Harnessing the code of life to develop new treatments
AstraZeneca launches integrated genomics approach to transform drug discovery and development
AstraZeneca supports World Ovarian Cancer Day 2016 - Play the Know and Tell game
At AstraZeneca, we are committed to raising awareness of ovarian cancer to ensure that every woman is fully informed about the symptoms and the impact of the disease. It is our goal to leave “no woman untold” about the disease.
AstraZeneca’s scientific leadership in lung cancer
Researchers from around the world came together in April to discuss cutting-edge lung cancer research at the European Lung Cancer Conference (ELCC) in Geneva, Switzerland. AstraZeneca and its global biologics research and development arm, MedImmune presented a wide range of data across their leading lung cancer portfolio.
Showcasing the next wave of scientific innovation – the IMED Biotech Unit Annual Review 2015
Find out more about the cutting edge science and technology driving our scientific leadership ambition forward, and how IMED is looking to the future – exploring and investing in the next wave of scientific innovation.
Working together to beat the rising threat of drug-resistant infections
AstraZeneca and other key players from across the global biopharmaceutical industry are calling on governments and industry to work together in taking comprehensive action against drug-resistant infections, with a joint declaration launched today at the World Economic Forum in Davos, Switzerland.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.
We partner with others around the world, combining the great science in our labs with complementary technologies, know-how and molecules to accelerate the delivery of new life-changing medicines.
Page Atlas ID: 970733.011
Date of next review: April 2017